ArticleAmerican journal of ophthalmology2014
Success with single-agent immunosuppression for multifocal choroidopathies.
Article in American journal of ophthalmology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Adalimumab versus Conventional Immunosuppression for Uveitis (ADVISE) Trial.Ophthalmology · 2026Trial
- Reactivation of Choroidal Neovascularization in Bilateral Punctate Inner Choroidopathy: A Case Report.Cureus · 2026Article
- Association of Risk Variants in the CFH Gene With Elevated Levels of Coagulation and Complement Factors in Idiopathic Multifocal Choroiditis.JAMA ophthalmology · 2023Article
- Analyzing the demographics of patients with uveitis in an indigent, urban population.BMC ophthalmology · 2023Article
- The Conundrum of Clinical Trials for the Uveitides: Appropriate Outcome Measures for One Treatment Used in Several Diseases.Epidemiologic reviews · 2022Article
- Mechanisms, Pathophysiology and Current Immunomodulatory/Immunosuppressive Therapy of Non-Infectious and/or Immune-Mediated Choroiditis.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Article
- Idiopathic multifocal choroiditis and punctate inner choroidopathy: an evaluation in pregnancy.Acta ophthalmologica · 2022Article
- Classification Criteria for Punctate Inner Choroiditis.American journal of ophthalmology · 2021Article
- Classification Criteria for Birdshot Chorioretinitis.American journal of ophthalmology · 2021Article
- Central Multifocal Choroiditis: Platelet Granularity as a Potential Marker for Treatment With Steroid-Sparing Immunomodulatory Therapy.Frontiers in ophthalmology · 2021Article
- The efficacy of adalimumab in treating patients with central multifocal choroiditis.American journal of ophthalmology case reports · 2020Article
- Update in treatment of uveitic macular edema.Drug design, development and therapy · 2019Review
- Immunosuppression for the Uveitides.Ophthalmology · 2018Review
- Spatial agreement between Goldmann visual field defects and fundus autofluorescence in patients with birdshot chorioretinopathy.Journal of ophthalmic inflammation and infection · 2016Article
- Multifocal Choroiditis and Panuveitis - difficulties in diagnosis and treatment.Romanian journal of ophthalmologyArticle
- Choriocapillaris Involvement in Acute Syphilis Posterior Placoid Chorioretinitis is Responsible for Functional Impairment and Points towards an Immunologic Mechanism: A Comprehensive Clinicopathological Approach.Journal of current ophthalmologyArticle
- Choroidal neovascularization secondary to ocular syphilis.Romanian journal of ophthalmologyArticle
- Multifocal Choroiditis with Retinal Vasculitis, Optic Neuropathy, and Keratoconus in a Young Saudi Male.Middle East African journal of ophthalmologyArticle
- Idiopathic Multifocal Choroiditis.Journal of ophthalmic & vision researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
purposeTo evaluate the success of single-agent immunosuppression for patients with the posterior uveitides, birdshot chorioretinitis, multifocal choroiditis with panuveitis, and punctate inner choroiditis.
designRetrospective case series.
methodssetting: Tertiary care uveitis practices. population: Patients initiated on immunomodulatory therapy. intervention: Patients were treated with prednisone 1 mg/kg and mycophenolate 2 g daily. Prednisone was tapered after 1 month. Immunosuppression was escalated to mycophenolate 3 g daily, with addition of a second agent, as needed, to achieve treatment success. outcome measure: Treatment success, defined as no disease activity with prednisone dose ≤10 mg daily, at 6, 12, and 24 months.
resultsTwenty-seven patients were followed. Mean presentation and 2-year follow-up acuities were 20/41 and 20/42, respectively. For birdshot chorioretinitis, mean (±standard deviation) quantitative Goldmann visual field scores improved from 761 ± 69 degrees (IV/4 isopter) and 496 ± 115 degrees (I/4 isopter) at presentation to 784 ± 57 degrees and 564 ± 125 degrees, respectively. Prednisone was successfully tapered in 95% of patients; mean prednisone doses at 1 and 2 years were 5.3 ± 4.1 and 5.7 ± 4.8 mg/day, respectively. At 2 years, prednisone was discontinued in 11% of patients. Treatment success was achieved in 74% of patients on 1 immunosuppressant, and in an additional 21% of patients on 2 agents, for an overall 95% success rate at 2 years.
conclusionsPosterior uveitides can be treated with 1 agent in most patients, but the data suggest a need to escalate therapy to higher mycophenolate doses, and in one fifth of cases to add a second agent to maintain disease suppression with acceptably low prednisone doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.